Trimethoprim-sulfamethoxazole therapy did not reduce time to death, lung transplant, or hospitalization in patients with moderate or severe idiopathic pulmonary fibrosis.
Researchers sought to determine if selexipag can be associated with lower hospitalization rates through analysis of real-world hospitalization rates of patients taking either selexipag or treprostinil.
In patients with aspirin exacerbated respiratory disease, treatment with omalizumab resulted in “clinically silent” aspirin desensitization.
Budesonide-formoterol as needed was not inferior compared with budesonide maintenance therapy in terms of severe asthma exacerbation rates, but may be inferior for controlling symptoms.
There was a 60% lower rate of severe asthma exacerbations in individuals treated with budesonide-formoterol compared with individuals treated with terbutaline as needed.
Early clinical response rates were similar across PORT risk class subgroups in patients with community-acquired bacterial pneumonia when treated with omadacycline or moxifloxacin.
PCV13, marketed as Prevnar 13, was evaluated in a test-negative case-control study in real-world conditions where patients were administered pneumococcal vaccination as advised by their healthcare providers.
Liberal supplemental oxygen therapy in acutely ill patients increased mortality during hospitalization, at 30 days, and at longest follow-up.
In the LEAP 2 study (N=738), patients with moderate CABP received either oral lefamulin 600mg every 12 hours for 5 days or oral moxifloxacin 400mg once daily for 7 days.
In patients with acute respiratory failure, high-flow nasal cannula and conventional oxygen therapy provided similar benefits.
